[{"id":"c2957436-cc4b-46f1-b57e-c905761bf625","acronym":"","url":"https://clinicaltrials.gov/study/NCT02626715","created_at":"2021-01-18T12:45:57.284Z","updated_at":"2024-07-02T16:35:25.740Z","phase":"Phase 2","brief_title":"Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS","source_id_and_acronym":"NCT02626715","lead_sponsor":"Randy Windreich","biomarkers":" FLT3 • CD34","pipe":" | ","alterations":" FLT3 positive","tags":["FLT3 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • melphalan • fludarabine IV • hydroxyurea • thiotepa • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 09/04/2015","start_date":" 09/04/2015","primary_txt":" Primary completion: 04/12/2023","primary_completion_date":" 04/12/2023","study_txt":" Completion: 04/12/2023","study_completion_date":" 04/12/2023","last_update_posted":"2023-12-19"},{"id":"083867de-5a50-4a67-ac63-c11e42dc2513","acronym":"","url":"https://clinicaltrials.gov/study/NCT05432401","created_at":"2022-06-27T14:54:11.243Z","updated_at":"2024-07-02T16:36:08.274Z","phase":"Phase 1","brief_title":"TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05432401","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" FLT3 • IL6","pipe":" | ","alterations":" FLT3 expression • FLT3 positive","tags":["FLT3 • IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 expression • FLT3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAA05"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/09/2022","start_date":" 06/09/2022","primary_txt":" Primary completion: 06/09/2023","primary_completion_date":" 06/09/2023","study_txt":" Completion: 06/09/2025","study_completion_date":" 06/09/2025","last_update_posted":"2022-06-27"},{"id":"449f97aa-36f9-4e3c-b3e9-6a9633ccaea5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05383014","created_at":"2022-05-19T11:56:24.419Z","updated_at":"2024-07-02T16:36:10.171Z","phase":"","brief_title":"FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia.","source_id_and_acronym":"NCT05383014","lead_sponsor":"Assiut University","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 expression • FLT3 positive","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 expression • FLT3 positive"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2022-05-19"},{"id":"dfaad6a0-3889-459b-9507-38a2e33f855a","acronym":"FLAM","url":"https://clinicaltrials.gov/study/NCT03547258","created_at":"2021-01-18T17:27:52.639Z","updated_at":"2024-07-02T16:36:45.759Z","phase":"","brief_title":"Italian Non-Interventional Study of FLT3 Mutated AML Patients","source_id_and_acronym":"NCT03547258 - FLAM","lead_sponsor":"Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori","biomarkers":" TP53 • FLT3 • IDH2 • WT1 • CEBPA","pipe":" | ","alterations":" FLT3 mutation • FLT3 positive","tags":["TP53 • FLT3 • IDH2 • WT1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 positive"],"overall_status":"Unknown status","enrollment":" Enrollment 800","initiation":"Initiation: 07/18/2018","start_date":" 07/18/2018","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 05/01/2021","study_completion_date":" 05/01/2021","last_update_posted":"2020-04-21"}]